Related Experiment Video
Updated: Sep 22, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties
Hayder M Al-Kuraishy1, Ali I Al-Gareeb1, Maisra M El-Bouseary2
1Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.
Insights
Hyperviscosity syndrome (HVS) is linked to COVID-19 and vaccines, especially in those with prior infection or metabolic issues. Increased fibrinogen and immunoglobulins may cause HVS, but more research is needed to confirm causality.
Area of Science:
- Internal Medicine
- Immunology
- Cardiology
Background:
- Hyperviscosity syndrome (HVS) is a recognized complication of viral infections.
- COVID-19 and its vaccines have been anecdotally linked to HVS development.
- HVS can lead to significant cardiovascular and neurological complications.
Purpose of the Study:
- To critically review and establish the association between COVID-19, COVID-19 vaccines, and the development of HVS.
- To explore the potential mechanisms underlying HVS in the context of COVID-19 and vaccination.
Main Methods:
- Critical review of existing literature.
- Analysis of immunological and hematological factors potentially contributing to HVS.
- Examination of clinical outcomes associated with HVS in COVID-19 patients.
Main Results:
- COVID-19 can increase blood viscosity (BV) by altering fibrinogen, albumin, lipoproteins, and RBC indices.
- HVS in COVID-19 is associated with cardiovascular events (MI, stroke) and reduced tissue oxygenation, potentially contributing to long COVID.
- HVS may occur in vaccine recipients, particularly those with prior COVID-19 or metabolic syndrome, due to elevated immunoglobulin levels.
Conclusions:
- COVID-19 and its vaccines are associated with HVS, especially in individuals with prior infection and metabolic derangements.
- Elevated fibrinogen and immunoglobulins are proposed mechanisms for HVS, with dehydration, oxidative stress, and inflammation as contributing factors.
- Further prospective and retrospective studies are required to definitively establish a causal relationship between COVID-19/vaccines and HVS.
Abstract:
Hyperviscosity syndrome (HVS) recently emerged as a complication of coronavirus disease 2019 (COVID-19) and COVID-19 vaccines. Therefore, the objectives of this critical review are to establish the association between COVID-19 and COVID-19 vaccines with the development of HVS. HVS may develop in various viral infections due to impairment of humoral and cellular immunity with elevation of immunoglobulins. COVID-19 can increase blood viscosity (BV) through modulation of fibrinogen, albumin, lipoproteins, and red blood cell (RBC) indices. HVS can cause cardiovascular and neurological complications in COVID-19 like myocardial infarction (MI) and stroke. HVS with or without abnormal RBCs function in COVID-19 participates in the reduction of tissue oxygenation with the development of cardio-metabolic complications and long COVID-19. Besides, HVS may develop in vaccine recipients with previous COVID-19 due to higher underlying Ig concentrations and rarely without previous COVID-19. Similarly, patients with metabolic syndrome are at the highest risk for propagation of HVS after COVID-19 vaccination. In conclusion, COVID-19 and related vaccines are linked with the development of HVS, mainly in patients with previous COVID-19 and underlying metabolic derangements. The possible mechanism of HVS in COVID-19 and related vaccines is increasing levels of fibrinogen and immunoglobulins. However, dehydration, oxidative stress, and inflammatory reactions are regarded as additional contributing factors in the pathogenesis of HVS in COVID-19. However, this critical review cannot determine the final causal relationship between COVID-19 and related vaccines and the development of HVS. Prospective and retrospective studies are warranted in this field.
More Related Videos
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...